UK Guide · Updated October 2026 · Reviewed by our superintendent pharmacist
“Microdosing” is all over social media. Here is what is licensed, what the trials show, and the safer ways to deal with cost and side effects.
The short answer
Microdosing Mounjaro is not a licensed regimen, and there is no published trial evidence that it works for weight loss. The licensed schedule starts at 2.5mg weekly for four weeks, then 5mg, and the 5mg dose alone averaged 15.0% weight loss over 72 weeks in the SURMOUNT-1 trial. Splitting pens or stretching them beyond their labelled doses risks inaccurate dosing and contamination. If side effects or cost are the problem, a pharmacist can hold you on a lower licensed dose, which is a safe, supervised alternative.
“Microdosing” has become one of the most-searched phrases around weight-loss injections. There is no medical definition of it. In practice, people use the word for three quite different things: taking a deliberately small amount of tirzepatide each week, dividing a pen's contents so one pen stretches across many more injections than it was designed for, or staying on a very low dose indefinitely instead of moving up the schedule.
At our Timperley pharmacy, we hear the question most weeks, and the motives are nearly always reasonable: the cost of treatment, nausea that has been hard to shake, or fear of the next dose increase. So this post is not a telling-off. It is the honest answer I would give you across the counter: what is licensed, what the evidence shows, what the risks are, and what we can safely do instead.
Mounjaro (tirzepatide) is licensed in the UK with a defined schedule. The starting dose is 2.5mg once weekly for four weeks, which is a starter dose to let your body adjust rather than a treatment dose. After four weeks it goes up to 5mg, and any further increases are in 2.5mg steps after at least four weeks on the current dose. The usual maintenance doses are 5mg, 10mg or 15mg, with 15mg the maximum.
The big pivotal obesity trial, SURMOUNT-1 (2,539 adults without diabetes, 72 weeks), tested 5mg, 10mg and 15mg against placebo. Average weight loss was 15.0%, 19.5% and 20.9% respectively, compared with 3.1% on placebo. Every one of those numbers comes from fixed doses delivered by the licensed schedule, with a 20-week escalation period.
What that means for microdosing: nobody has published trial evidence on weekly doses below the 2.5mg starter, or on irregular partial doses, for weight loss. The honest position is that we do not know what they do, how long they last, or how safe they are over months. Anyone telling you microdosing delivers “the same results with none of the side effects” is selling a claim the trials do not support. Remember too that results vary between individuals, and no one can promise an outcome.
| Feature | Licensed schedule | “Microdosing” |
|---|---|---|
| Dose amount | Fixed 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg or 15mg | Improvised partial amounts |
| Doses per pen | Four, as labelled | Often stretched beyond four |
| Trial evidence for weight loss | Yes, SURMOUNT-1 and others | None published |
| Dose accuracy | Set by the pen mechanism | Depends on home measuring |
| Contamination risk | Sealed pen, single-patient use | Raised if drawn up or reused |
| Who decides the dose | Your pharmacist, at review | You, or a seller online |
| Reporting side effects | Clear route via pharmacist and Yellow Card | Often unclear what you took |
The Mounjaro KwikPen is a fixed-dose device: a 2.5mg pen holds four 2.5mg doses, and the patient leaflet is explicit that you should not try to use any medicine left in the pen after the correct doses have been given. It was not designed to be divided, and these are the risks I worry about when someone does it anyway:
None of this means that a lower dose is wrong. It means that the way you get to a lower dose matters.
1. Side effects. Nausea, constipation and reflux are the most common reasons people look for a gentler approach, and they are strongly linked to dose increases. In SURMOUNT-1, nausea affected 24.6% of people on 5mg and around a third on 10mg and 15mg, versus 9.5% on placebo, and 4.3% to 7.1% stopped treatment because of adverse events. The licensed solution is simple: stay on your current licensed dose for longer, or step back to the last dose you tolerated, and use the practical tips in our week-by-week side-effect guide.
2. Cost. Treatment is a real monthly expense. See the section below, and our full price guide. Stretching a pen is a false economy if it costs you accuracy, safety and results.
3. Fear of staying on it for life. Understandable, and a conversation worth having. Our guide to coming off injections without regaining explains how a supervised, gradual plan works far better than an improvised one.
4. Stalled weight loss. Some people think more is not better and go lower, but a plateau usually has other causes. See weight-loss plateaus on Mounjaro or Wegovy before changing the dose.
Our current monthly prices for Mounjaro are £160 at 2.5mg, £190 at 5mg, £280 at 10mg and £300 at 15mg, so staying on a lower licensed dose that is working for you does cost less than climbing the schedule. That is a legitimate clinical choice, as long as it is made at a review and not by improvising. Where you are doing well at 5mg, a pharmacist can talk through whether stepping up is actually needed.
If a different medicine might suit you better, our treatment chooser and Wegovy pages set out the alternatives. Treatment is always decided face-to-face, and you can check whether you are suitable first with our suitability check. Prices can change, so confirm the current figure when you book.
Most microdosing advice online comes from influencers, forums and sellers, rather than from trials or regulators. Before you act on any of it, ask four questions. Who is telling me this, and are they selling something? Is the claim based on a published trial, or on someone's personal experience? Does it rely on a product that is not a licensed UK medicine? And would the person advising me ever see me, weigh me and review me again?
Personal stories can be sincere and still misleading. Someone who loses weight on a small dose may be losing it because of changes to eating, activity or sleep, because the effect of the first few weeks is real at any dose, or simply by chance. Without a control group, nobody can separate those explanations. That is exactly why trials such as SURMOUNT-1 compare treatment with placebo, and why we put more weight on them than on a viral post.
There is also a mismatch between marketing and the regulator. The MHRA and other UK bodies have repeatedly warned businesses against promoting prescription-only weight-loss medicines to the public. A seller who advertises a prescription medicine directly, and pairs it with a tempting low-dose promise, is breaking the rules before you have even met them.
If you are tempted to change your dose, a short, honest conversation will usually get you further than any workaround. These are the questions I would bring to a review:
A good pharmacist will not be offended by any of these, and none of them requires you to hide what you have been doing. If you have missed doses, stretched a pen, or bought something online, say so. We would much rather know, so that we can keep you safe.
We follow the licensed, manufacturer-approved dosing schedule and review every patient in person at least monthly. We do not supply microdosing regimens or encourage dose-splitting. What we do offer is flexibility inside the licence:
For the wider regulatory picture, see our short explainer on what microdosing is.
WeightGone UK is a GPhC-registered pharmacy (registration 1118728) in Timperley, Altrincham, seeing patients from Sale, Hale, Stretford, Wythenshawe and across Greater Manchester. If you have been thinking about microdosing, or already tried it, you do not need to pretend otherwise. Bring any pens you have and we will help you work out a safe next step, without judgement.
Sources
Published 5 October 2026. Written and clinically reviewed by the WeightGone UK pharmacy team. This article is information, not a prescription, and suitability is always confirmed face-to-face. Results vary between individuals and no outcome is guaranteed.
It usually means taking less than the licensed dose of tirzepatide, most often by dividing a pen's contents into smaller amounts, using a dose lower than 2.5mg, or stretching one pen across far more than four injections. None of these is a licensed way to use Mounjaro. The licensed schedule starts at 2.5mg once weekly for four weeks, then 5mg, with further steps of 2.5mg at least four weeks apart if needed.
Taking a medicine you have been prescribed isn't a crime, but microdosing isn't an approved regimen, and a prescriber supplying it is working outside the licence. Anyone selling pens, vials or kits for splitting without a proper clinical assessment is a red flag. Our post on buying weight-loss injections safely explains how to check a seller on the GPhC register.
There is no trial evidence that it does. In the SURMOUNT-1 trial, the lowest tested maintenance dose (5mg) produced an average 15.0% weight loss at 72 weeks, against 3.1% on placebo, but those results were achieved on the licensed dose schedule with careful supervision, not on improvised partial doses. Anything below that has not been studied for obesity, so we cannot tell you what to expect from it.
Often, yes, because gastrointestinal side effects tend to be dose-related and appear mainly during dose increases. In SURMOUNT-1, nausea affected 24.6% on 5mg, 33.3% on 10mg and 31.0% on 15mg, against 9.5% on placebo. But the licensed way to ease side effects is to hold at a dose longer or step back to the last tolerated licensed dose with your pharmacist, not to split pens at home.
Mounjaro KwikPens are built to deliver fixed doses, and each pen holds four. The patient leaflet tells you not to use any medicine left in the pen after the correct doses have been given. Drawing medicine out with syringes or needles, or using a pen beyond its labelled doses, risks inaccurate amounts, contamination and using medicine past its in-use limit. It is also how many unregulated 'kits' are marketed.
Staying on a licensed dose that is working for you is a normal clinical decision. 5mg is itself a licensed maintenance dose, and a pharmacist can hold you on a dose for longer before stepping up if side effects are still settling. What matters is that the decision is made at a review, with your weight and symptoms in front of us, rather than by quietly skipping or splitting doses.
Tell your pharmacist before you change anything. At our pharmacy the monthly price rises with dose, so staying on a lower licensed dose can cost less, and in some cases a switch to a different licensed treatment may be a better fit. We will give you honest options rather than judge the question. Do not stretch a pen over more weeks than the dose schedule allows.
Don't panic and don't stop being honest with whoever treats you. Keep any pens and packaging, stop re-drawing doses from pens, and book a review so a pharmacist can check your weight, symptoms and where you have got to on the licensed schedule. Report any suspected side effect or defective product through the MHRA Yellow Card scheme. This post is general information, not a prescription, and suitability is always confirmed face-to-face.
Medically reviewed by Muhammad Adnan, GPhC-registered Superintendent Pharmacist · Last updated June 2026.
This article is general information and isn't a substitute for personal medical advice. Your pharmacist will assess what's right for you at a face-to-face consultation. More health advice · Book a consultation.
WeightGone